Radiopharmaceutical · developed by AstraZeneca
[111In]-FPI-2107 is an imaging agent consisting of indium-111 conjugated to FPI-2053. It is being studied in advanced solid tumors including colorectal, head and neck, lung, pancreatic, gastric, and renal cell carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06147037 | Phase 1 | Advanced Solid Tumor | Active not recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorGastric CancerHead and Neck Squamous Cell CarcinomaMetastatic Colorectal CarcinomaNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaRenal Cell Carcinoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →